{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:08:37Z","timestamp":1780927717792,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2009,9,16]],"date-time":"2009-09-16T00:00:00Z","timestamp":1253059200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s00228-009-0712-x","type":"journal-article","created":{"date-parts":[[2009,9,15]],"date-time":"2009-09-15T07:02:54Z","timestamp":1252998174000},"page":"1187-1193","source":"Crossref","is-referenced-by-count":49,"title":["Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling"],"prefix":"10.1007","volume":"65","author":[{"given":"Dechun","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangrong","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,9,16]]},"reference":[{"key":"712_CR1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.5414\/CPP46157","volume":"46","author":"B Georges","year":"2008","unstructured":"Georges B, Conil JM, Seguin T et al (2008) Cefepime in intensive care unit patients: validation of a population pharmacokinetic approach and influence of covariables. Int J Clin Pharmacol Ther 46:157\u2013164","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"712_CR2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2125.2008.03139.x","volume":"65","author":"PL Chan","year":"2008","unstructured":"Chan PL, Weatherley B, McFadyen L (2008) A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. Br J Clin Pharmacol 65(Suppl 1):76\u201385","journal-title":"Br J Clin Pharmacol"},{"key":"712_CR3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/0091270007313391","volume":"48","author":"B Punyawudho","year":"2008","unstructured":"Punyawudho B, Ramsay RE, Macias FM et al (2008) Population pharmacokinetics of lamotrigine in elderly patients. J Clin Pharmacol 48:455\u2013463","journal-title":"J Clin Pharmacol"},{"key":"712_CR4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.tpj.6500210","volume":"3","author":"PC Ho","year":"2003","unstructured":"Ho PC, Abbott FS, Zanger UM et al (2003) Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J 3:335\u2013342","journal-title":"Pharmacogenomics J"},{"key":"712_CR5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1358\/mf.2007.29.10.1116313","volume":"29","author":"SM Jankovic","year":"2007","unstructured":"Jankovic SM, Milovanovic JR (2007) Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients. Methods Find Exp Clin Pharmacol 29:673\u2013679","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"712_CR6","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/j.1745-7254.2007.00704.x","volume":"28","author":"DC Jiang","year":"2007","unstructured":"Jiang DC, Wang L, Wang YQ et al (2007) Population pharmacokinetics of valproate in children with epilepsy in Chinese. Acta Pharmacol Sin 28:1677\u20131684","journal-title":"Acta Pharmacol Sin"},{"key":"712_CR7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/toxsci\/kfl096","volume":"94","author":"TK Kiang","year":"2006","unstructured":"Kiang TK, Ho PC, Anari MR et al (2006) Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1\/*1 genotype. Toxicol Sci 94:261\u2013271","journal-title":"Toxicol Sci"},{"key":"712_CR8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.mjt.0000155113.89092.58","volume":"13","author":"NA Panomvana","year":"2006","unstructured":"Panomvana NA, Ayudhya D, Suwanmanee J (2006) Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children. Am J Ther 13:211\u2013217","journal-title":"Am J Ther"},{"key":"712_CR9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10928-005-0034-2","volume":"32","author":"S Duffull","year":"2005","unstructured":"Duffull S, Waterhouse T, Eccleston J (2005) Some considerations on the design of population pharmacokinetic studies. J Pharmacokinet Pharmacodyn 32:441\u2013457","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"712_CR10","doi-asserted-by":"crossref","first-page":"E475","DOI":"10.1208\/aapsj070248","volume":"7","author":"B Meibohm","year":"2005","unstructured":"Meibohm B, Laer S, Panetta JC (2005) Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 7:E475\u2013E487","journal-title":"AAPS J"},{"key":"712_CR11","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","volume":"269","author":"SMF Morais De","year":"1994","unstructured":"De Morais SMF, Wilkinson GR, Blaisdell J et al (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419\u201315422","journal-title":"J Biol Chem"},{"key":"712_CR12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00008571-199710000-00011","volume":"7","author":"K Nasu","year":"1997","unstructured":"Nasu K, Kubota T, Ishizaki T (1997) Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 7:405\u2013409","journal-title":"Pharmacogenetics"},{"key":"712_CR13","first-page":"175","volume":"66","author":"HG Xie","year":"2000","unstructured":"Xie HG (2000) Genetic variations of S-mephenytoin 4\u2032-hydroxylase (CYP2C19) in the Chinese population. Life Sci 66:175\u2013181","journal-title":"Life Sci"},{"key":"712_CR14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1472-8206.2003.00148.x","volume":"17","author":"JQ Yang","year":"2003","unstructured":"Yang JQ, Morin S, Verstuyft C et al (2003) Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam Clin Pharmacol 17:373\u2013376","journal-title":"Fundam Clin Pharmacol"},{"key":"712_CR15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00228-008-0493-7","volume":"64","author":"K Ogungbenro","year":"2008","unstructured":"Ogungbenro K, Aarons L (2008) How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach. Eur J Clin Pharmacol 64:705\u2013713","journal-title":"Eur J Clin Pharmacol"},{"key":"712_CR16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2125.2007.02975.x","volume":"64","author":"C Dartois","year":"2007","unstructured":"Dartois C, Brendel K, Comets E et al (2007) Overview of model-building strategies in population PK\/PD analyses: 2002\u20132004 literature survey. Br J Clin Pharmacol 64:603\u2013612, Comment in: Br J Clin Pharmacol 64: 578\u2013579","journal-title":"Br J Clin Pharmacol"},{"key":"712_CR17","doi-asserted-by":"crossref","first-page":"E60","DOI":"10.1208\/aapsj0901007","volume":"9","author":"RJ Bauer","year":"2007","unstructured":"Bauer RJ, Guzy S, Ng C (2007) A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 9:E60\u2013E83","journal-title":"AAPS J"},{"key":"712_CR18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2125.2004.02241.x","volume":"59","author":"BS Kappelhoff","year":"2005","unstructured":"Kappelhoff BS, Huitema AD, Crommentuyn KM et al (2005) Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients. Br J Clin Pharmacol 59:174\u2013182","journal-title":"Br J Clin Pharmacol"},{"key":"712_CR19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1528-1157.1998.tb01330.x","volume":"39","author":"K Mamiya","year":"1998","unstructured":"Mamiya K, Ieiri I, Shimamoto J et al (1998) The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 39:1317\u20131323","journal-title":"Epilepsia"},{"key":"712_CR20","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/00007691-200410000-00012","volume":"26","author":"CC Hung","year":"2004","unstructured":"Hung CC, Lin CJ, Chen CC (2004) Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9\/CYP2C19 polymorphisms. Ther Drug Monit 26:534\u2013540","journal-title":"Ther Drug Monit"},{"key":"712_CR21","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s002280050703","volume":"55","author":"K Mamiya","year":"2000","unstructured":"Mamiya K, Hadama A, Yukawa E et al (2000) CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol 55:821\u2013825","journal-title":"Eur J Clin Pharmacol"},{"key":"712_CR22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/FTD.0b013e318030def0","volume":"29","author":"S Goto","year":"2007","unstructured":"Goto S, Seo T, Murata T et al (2007) Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese. Ther Drug Monit 29:118\u2013121","journal-title":"Ther Drug Monit"},{"key":"712_CR23","first-page":"1576","volume":"25","author":"DC Jiang","year":"2004","unstructured":"Jiang DC, Wang L (2004) Population pharmacokinetic model of valproate and prediction of valproate serum concentrations in children with epilepsy. Acta Pharmacol Sin 25:1576\u20131583","journal-title":"Acta Pharmacol Sin"},{"key":"712_CR24","first-page":"735","volume":"24","author":"G Wang","year":"2004","unstructured":"Wang G, Gu R, Liu B (2004) Population pharmacokinetics of valproic acid in children. Chin J Hosp Pharm 24:735\u2013738","journal-title":"Chin J Hosp Pharm"},{"key":"712_CR25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00228-003-0699-7","volume":"59","author":"ES Desoky El","year":"2004","unstructured":"El Desoky ES, Fuseau E, El Din Amry S (2004) Pharmacokinetic modeling of valproic acid from routine clinical data in Egyptian epileptic patients. Eur J Clin Pharmacol 59:783\u2013790","journal-title":"Eur J Clin Pharmacol"},{"key":"712_CR26","first-page":"515","volume":"24","author":"Z Jiao","year":"2004","unstructured":"Jiao Z, Zhong MK, Hu M et al (2004) Population pharmacokinetic modeling of valproic acid clearance. Chin J Hosp Pharm 24:515\u2013517","journal-title":"Chin J Hosp Pharm"},{"key":"712_CR27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2710.2002.00440.x","volume":"27","author":"HM Park","year":"2003","unstructured":"Park HM, Kang SS, Lee YB et al (2003) Population pharmacokinetics of intravenous valproic acid in Korean patients. J Clin Pharm Ther 27:419\u2013425","journal-title":"J Clin Pharm Ther"},{"key":"712_CR28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1046\/j.1365-2710.2003.00528.x","volume":"28","author":"E Yukawa","year":"2003","unstructured":"Yukawa E, Nonaka T, Yukawa M (2003) Pharmacoepidemiologic investigation of a clonazepam-valproic acid interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients. J Clin Pharm Ther 28:497\u2013504","journal-title":"J Clin Pharm Ther"},{"key":"712_CR29","first-page":"95","volume":"1","author":"M Hu","year":"2001","unstructured":"Hu M, Zhang JH, Sun H et al (2001) Construction and clinical application of the population pharmacokinetic model of valproic acid. Evaluat Anal Drug-use Hosp China 1:95\u201397","journal-title":"Evaluat Anal Drug-use Hosp China"},{"key":"712_CR30","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.clinthera.2005.05.001","volume":"27","author":"KC Carlsson","year":"2005","unstructured":"Carlsson KC, Hoem NO, Glauser T (2005) Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy. Clin Ther 27:618\u2013626","journal-title":"Clin Ther"},{"key":"712_CR31","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2125.2008.03118.x","volume":"65","author":"D Hirt","year":"2008","unstructured":"Hirt D, Van Overmeire B, Treluyer JM et al (2008) An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. Br J Clin Pharmacol 65:629\u2013636","journal-title":"Br J Clin Pharmacol"},{"key":"712_CR32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00228-007-0412-3","volume":"64","author":"C Nyakutira","year":"2008","unstructured":"Nyakutira C, R\u00f6shammar D, Chigutsa E et al (2008) High prevalence of the CYP2B6 516G\u2013>T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV\/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 64:357\u2013365","journal-title":"Eur J Clin Pharmacol"},{"key":"712_CR33","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1248\/bpb.29.772","volume":"29","author":"M Honda","year":"2006","unstructured":"Honda M, Ogura Y, Toyoda W et al (2006) Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers. Biol Pharm Bull 29:772\u2013778","journal-title":"Biol Pharm Bull"},{"key":"712_CR34","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1007\/s11095-008-9638-8","volume":"25","author":"VV Kumar","year":"2008","unstructured":"Kumar VV, Duffull SB (2008) Methods to account for inaccuracies in the dosing history when performing population pharmacokinetic analysis. Pharm Res 25:2740\u20132749","journal-title":"Pharm Res"},{"key":"712_CR35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1742-7843.2007.00061.x","volume":"100","author":"A Gunes","year":"2007","unstructured":"Gunes A, Bilir E, Zengil H (2007) Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. Basic Clin Pharmacol Toxicol 100:383\u2013386","journal-title":"Basic Clin Pharmacol Toxicol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0712-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-009-0712-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0712-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T18:51:28Z","timestamp":1633891888000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-009-0712-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,16]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["712"],"URL":"https:\/\/doi.org\/10.1007\/s00228-009-0712-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,16]]}}}